LAGUNA HILLS, Calif., Sept. 7, 2011 /PRNewswire/ -- NanoSmart™ Pharmaceuticals, Inc., a biopharmaceutical corporation developing novel cancer pharmaceuticals, has moved into its new corporate facility located in Laguna Hills, CA. The facility provides the administrative and laboratory work space necessary to begin formal development of its initial product pipeline.
"Our new location gives us a physical presence in Orange County, California and allows us to move forward with our strategic development goals," said Dr. Henry Smith, CEO of the company. "We are excited about the opportunity to develop our initial products and conduct formal, nonclinical studies leading towards our initial regulatory filings," said Dr. Smith.
About the technology:
NanoSmart™ is developing a patented, novel anti-tumor targeting platform based on fully-human autoimmune antibodies. These antibodies target areas of necrosis found in many different types of cancer. NanoSmart's drug delivery system represents a versatile platform technology with many advantages, including improved localization of cancer therapeutics leading to increased safety and efficacy. By combining these antibodies with different cancer drugs, NanoSmart has the potential to develop a very large number of novel biopharmaceutical products.
NanoSmart™ Pharmaceuticals, Inc., is a privately-held company engaged in developing novel methods to treat cancer and other diseases. The company is focused on using its patented tumor targeting antibodies to develop a variety of biopharmaceuticals to treat many different types of cancer. This press release may contain forward-looking statements regarding future events. There can be no assurance that such development efforts will succeed; or that the novel biopharmaceuticals will receive regulatory clearance or achieve commercial success.
For more information contact us at (949) 305-2020
E-mail us at email@example.com
Investor Relations: (310) 951-3282
Please visit our website: www.nanosmartpharmaceuticals.com
SOURCE NanoSmart Pharmaceuticals, Inc.